MMC insider filing: Hopkins reports 19,752.73 shares after RSU award
Rhea-AI Filing Summary
Marsh & McLennan Companies director Deborah C. Hopkins reported receipt of restricted stock units under the company's Directors Stock Compensation Plan that convert 1-for-1 into common stock. The transaction dated 08/15/2025 shows 85.08 underlying shares (acquired with dividend equivalents) and reports 19,752.73 shares beneficially owned following the transaction on a direct basis. The filing was executed by an attorney-in-fact on 08/18/2025. No exercise price or derivative expiration applies because these are restricted stock units that convert to common stock.
Positive
- None.
Negative
- None.
Insights
TL;DR Director received a routine grant of RSUs converting to 85.08 shares; beneficial ownership now 19,752.73 shares.
This Form 4 documents a standard director compensation event under the Directors Stock Compensation Plan. The 85.08 restricted stock units were credited with dividend equivalents and convert 1-for-1 into common stock, consistent with the plan's mechanics. The incremental size of the grant is small relative to the total reported beneficial ownership, suggesting this is a routine, non-material equity compensation entry rather than a corporate governance or control signal.
TL;DR Routine director equity award; filing aligns with disclosure obligations and uses an attorney-in-fact signature.
The filing shows proper reporting of a director stock compensation event, including the use of dividend equivalents to acquire RSUs. The signature by an attorney-in-fact and the clear explanation that the RSUs convert 1-for-1 to common stock indicate standard administrative handling. There are no indications of accelerated vesting, sales, or unusual derivatives activity that would raise governance concerns.
FAQ
What did MMC director Deborah C. Hopkins report on Form 4?
How many MMC shares does Deborah C. Hopkins beneficially own after the transaction?
When was the transaction and who signed the Form 4?
Were the RSUs acquired with dividend equivalents or purchased outright?
Does this Form 4 involve exercised options or derivative securities?